P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Sanjay R. Mohan,Cristiana Costa Chase,Jesus G. Berdeja,Lionel Karlin,Karim Belhadj,Aurore Perrot,Philippe Moreau,Cyrille Touzeau,Thomas Chalopin,Alexander M. Lesokhin,Carol Ann Huff,David H. Vesole,Joshua Richter,Jeffrey Matous,Igor Proscurshim,Eileen Wolff,Girish S. Gudi,A. Garton,Vinu C A Menon,Sunitha Gn,Yacine Salhi,Eric J. Feldman,Mohamad Mohty +22 more
TL;DR: In this article , the authors report the results from the dose-escalation portion of an ongoing, multi-center, open-label, single-agent phase 1 study (NCT03309111) of ISB 1342 in patients with RRMM.
Journal ArticleDOI
Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).
N. W. C. J. van de Donk,Philippe Moreau,Michel Delforge,Hermann Einsele,Francesca Ghilotti,Joris Diels,Ahmed Elsada,Vadim Strulev,Lixia Pei,Rachel Kobos,Jennifer Smit,Mary Slavcev,Katja Weisel,Maria-Victoria Mateos +13 more
TL;DR: Tec showed significantly improved efficacy over RWCP for almost all outcomes, highlighting its potential as a highly effective tx option for pts with TCE RRMM who have been exposed to ≥3 LOT.
Journal ArticleDOI
Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
Cyrille Touzeau,Ajai Chari,Carolina Schinke,Monique C. Minnema,Jesus G. Berdeja,Albert Oriol,N. W. C. J. van de Donk,P. Rodriguez Otero,Elham Askari,Maria-Victoria Mateos,Luciano J. Costa,Jo Caers,Leo Rasche,Amrita Krishnan,Deeksha Vishwamitra,Xuewen JoAnn Ma,Xiang Qin,Katharine S. Gries,Kelly Kato,Michel Campagna,Tara Masterson,Brandi Hilder,Jaszianne A. Tolbert,Thomas Renaud,Jenna D. Goldberg,Christoph Heuck,Philippe Moreau,Jesús F. San Miguel +27 more
TL;DR: In this paper , the authors reported that patients with more advanced and heavily pretreated disease have worse health-related quality of life (HRQoL) than those at earlier stages.
Journal ArticleDOI
Pb2014: teclistamab vs selinexor-dexamethasone in patients with triple-class exposed relapsed/refractory multiple myeloma: a matching-adjusted indirect comparison
Laura Rosiñol,S. Usmani,N. Bahlis,Amrita Krishnan,A. Nooka,Albert Oriol,Margaux Delforge,Alfred L. Garfall,N. W. van de Donk,P. Rodriguez Otero,Thomas R. Martin,Joris Diels,Suzy Van Sanden,Lixia Pei,Eric A. Ammann,Rachel Kobos,Mary Slavcev,Jennifer Smit,Archana Londhe,Philippe Moreau +19 more
TL;DR: Teclistamab significantly improved efficacy over sel-dex for all outcomes except PFS (though numerically in favor of teclistAMab) in this unanchored MAIC, highlighting the potential of te clistamAB as a highly effective treatment option for patients with TCE RRMM who received at least 3 prior LOT.
Journal ArticleDOI
Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician’s choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Maria-Victoria Mateos,Ajai Chari,Saad Z. Usmani,Hartmut Goldschmidt,Katja Weisel,Keqin Qi,Anil Londhe,Sandhya Nair,Xiwu Lin,Lixia Pei,Eric A. Ammann,Rachel Kobos,Jennifer Smit,Trilok V. Parekh,Mary Slavcev,Philippe Moreau +15 more
TL;DR: Tec showed improved efficacy versus physician’s choice of therapy in all clinical outcomes, highlighting its therapeutic potential to address unmet needs in pts with TCE RRMM who received ≥3 prior LOT.